DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-99696 | Others
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Detection of biomarkers in acute myeloid leukemia (AML) Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET
7.1 GLOBAL DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA DETECTION OF BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 Thermo Fisher Scientific
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Cancer Genetics Inc
16.3 Epigenomics AG
16.4 Sysmex Corporation
16.5 Novartis AG
16.6 BioMerieux SA
16.7 Skyline DX BV
16.8 Abbott Laboratories
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
Major Types CoveredProteomics Biomarkers of Acute Myeloid Leukemia (AML)
Genetic acute myeloid leukemia (AML) biomarkers
Biomarkers of epigenetic acute myeloid leukemia (AML)
Major Downstream Industry Covered
hospital
Scientific research institutes
other
Cancer Diagnosis Center
Companies
Thermo Fisher Scientific
Cancer Genetics Inc
Epigenomics AG
Sysmex Corporation
Novartis AG
BioMerieux SA
Skyline DX BV
Abbott Laboratories
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.